Abstract
SBP is a serious and costly cirrhosis complication, with ∼50% of cases requiring ICU admission. Due to its demonstrated efficacy in critical care settings, albumin is recommended by the American Association for the Study of Liver Diseases as an adjuvant to antibiotics for the management of SBP. We examined the relationship between early albumin infusion and ICU cost in a subgroup of cirrhotic patients who developed SBP during hospitalization.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
